Application

VAXZEVRIA

AstraZeneca UK Limited

Trademark/Service Mark Application, Principal Register

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1478 (Rev 09/2006)
OMB No. 0651-0009 (Exp 02/28/2021)

Trademark/Service Mark Application, Principal Register

Serial Number: 90379679
Filing Date: 12/14/2020

The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 90379679
MARK INFORMATION
*MARK VAXZEVRIA
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT VAXZEVRIA
MARK STATEMENT The mark consists of standard characters, without claim to any particular font style, size, or color.
REGISTER Principal
APPLICANT INFORMATION
*OWNER OF MARK AstraZeneca UK Limited
INTERNAL ADDRESS 1 Francis Crick Avenue
*MAILING ADDRESS Cambridge Biomedical Campus
*CITY Cambridge
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United Kingdom
*ZIP/POSTAL CODE
(Required for U.S. and certain international addresses)
CB20AA
*EMAIL ADDRESS XXXX
LEGAL ENTITY INFORMATION
TYPE limited liability company
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY WHERE LEGALLY ORGANIZED United Kingdom
GOODS AND/OR SERVICES AND BASIS INFORMATION
INTERNATIONAL CLASS 005 
*IDENTIFICATION Pharmaceutical preparations and substances
FILING BASIS SECTION 1(b)
FILING BASIS SECTION 44(d)
       FOREIGN APPLICATION NUMBER UK00003555632
       FOREIGN APPLICATION
       COUNTRY/REGION/JURISDICTION/U.S. TERRITORY
United Kingdom
       FOREIGN FILING DATE 11/13/2020
       INTENT TO
       PERFECT 44(d)
At this time, the applicant intends to rely on Section 44(e) as a basis for registration and requests that the application be suspended to await the submission of the foreign registration. If ultimately the applicant does not rely on §44(e) as a basis for registration, a valid claim of priority may be retained.
ATTORNEY INFORMATION
NAME Wm. Charles Saunders
ATTORNEY BAR MEMBERSHIP NUMBER XXX
YEAR OF ADMISSION XXXX
U.S. STATE/ COMMONWEALTH/ TERRITORY XX
FIRM NAME AstraZeneca Pharmaceuticals LP
STREET 1800 Concord Pike, A2C
CITY Wilmington
STATE Delaware
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
ZIP/POSTAL CODE 19850-5437
PHONE 302-886-6934
FAX 302-885-3762
EMAIL ADDRESS chuck.saunders@astrazeneca.com
DOMESTIC REPRESENTATIVE INFORMATION
NAME Wm. Charles Saunders
FIRM NAME AstraZeneca Pharmaceuticals LP
STREET 1800 Concord Pike, A2C
CITY Wilmington
STATE Delaware
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
ZIP CODE 19850-5437
PHONE 302-886-6934
FAX 302-885-3762
EMAIL ADDRESS chuck.saunders@astrazeneca.com
CORRESPONDENCE INFORMATION
NAME Wm. Charles Saunders
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE chuck.saunders@astrazeneca.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) trademarks@astrazeneca.com; lori.tittley@astrazeneca.com
FEE INFORMATION
APPLICATION FILING OPTION TEAS Standard
NUMBER OF CLASSES 1
APPLICATION FOR REGISTRATION PER CLASS 275
*TOTAL FEES DUE 275
*TOTAL FEES PAID 275
SIGNATURE INFORMATION
SIGNATURE /wcs/
SIGNATORY'S NAME Wm. Charles Saunders
SIGNATORY'S POSITION Attorney of record, Pennsylvania bar member
SIGNATORY'S PHONE NUMBER 302-886-6934
DATE SIGNED 12/14/2020



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1478 (Rev 09/2006)
OMB No. 0651-0009 (Exp 02/28/2021)


Trademark/Service Mark Application, Principal Register

Serial Number: 90379679
Filing Date: 12/14/2020

To the Commissioner for Trademarks:

MARK: VAXZEVRIA (Standard Characters, see mark)
The literal element of the mark consists of VAXZEVRIA. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, AstraZeneca UK Limited, a limited liability company legally organized under the laws of United Kingdom, having an address of
      1 Francis Crick Avenue
      Cambridge Biomedical Campus
      Cambridge CB20AA
      United Kingdom
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 005:  Pharmaceutical preparations and substances
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

Priority based on foreign filing: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services and asserts a claim of priority based on United Kingdom application number UK00003555632, filed 11/13/2020.
INTENT TO PERFECT 44(d) : At this time, the applicant intends to rely on Section 44(e) as a basis for registration and requests that the application be suspended to await the submission of the foreign registration. If ultimately the applicant does not rely on §44(e) as a basis for registration, a valid claim of priority may be retained.




The owner's/holder's proposed attorney information: Wm. Charles Saunders. Wm. Charles Saunders of AstraZeneca Pharmaceuticals LP, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, is located at
      1800 Concord Pike, A2C
      Wilmington, Delaware 19850-5437
      United States
      302-886-6934(phone)
      302-885-3762(fax)
      chuck.saunders@astrazeneca.com

Wm. Charles Saunders submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant hereby appoints Wm. Charles Saunders of AstraZeneca Pharmaceuticals LP
      1800 Concord Pike, A2C
      Wilmington Delaware 19850-5437
      United States
      302-886-6934(phone)
      302-885-3762(fax)
      chuck.saunders@astrazeneca.com
as applicant's representative upon whom notice or process in the proceedings affecting the mark may be served.

The applicant's current Correspondence Information:
      Wm. Charles Saunders
       PRIMARY EMAIL FOR CORRESPONDENCE: chuck.saunders@astrazeneca.com
       SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): trademarks@astrazeneca.com; lori.tittley@astrazeneca.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $275 has been submitted with the application, representing payment for 1 class(es).

Declaration

Declaration Signature

Signature: /wcs/   Date: 12/14/2020
Signatory's Name: Wm. Charles Saunders
Signatory's Position: Attorney of record, Pennsylvania bar member
Payment Sale Number: 90379679
Payment Accounting Date: 12/14/2020

Serial Number: 90379679
Internet Transmission Date: Mon Dec 14 11:41:39 ET 2020
TEAS Stamp: USPTO/BAS-XX.XX.XX.XX-202012141141396719
67-90379679-7505e973925fa37fdd4d76d42cfa
8e4ab6e13e842c07c4de224b45771bf1dbf1ee-D
A-41390946-20201210200129876277

Application [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed